Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce ...

Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...

The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...

UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...

A newly launched $5 million clinical trial program allows clinical trial sponsors to start trials in as little as 45 days in the Canadian province Ontario. | A newly launched $5 million clinical trial ...

Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...

Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...

Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed ...

A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, ...